RU2565827C2 - Способ получения вирусного антигена и вакцин - Google Patents
Способ получения вирусного антигена и вакцин Download PDFInfo
- Publication number
- RU2565827C2 RU2565827C2 RU2014101484/10A RU2014101484A RU2565827C2 RU 2565827 C2 RU2565827 C2 RU 2565827C2 RU 2014101484/10 A RU2014101484/10 A RU 2014101484/10A RU 2014101484 A RU2014101484 A RU 2014101484A RU 2565827 C2 RU2565827 C2 RU 2565827C2
- Authority
- RU
- Russia
- Prior art keywords
- stage
- virus
- enveloped
- viral
- equal
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 163
- 230000003612 virological effect Effects 0.000 title claims abstract description 100
- 239000000427 antigen Substances 0.000 title claims abstract description 94
- 102000036639 antigens Human genes 0.000 title claims abstract description 94
- 108091007433 antigens Proteins 0.000 title claims abstract description 94
- 229960005486 vaccine Drugs 0.000 title claims abstract description 42
- 241000700605 Viruses Species 0.000 claims abstract description 154
- 239000003599 detergent Substances 0.000 claims abstract description 81
- 238000000746 purification Methods 0.000 claims abstract description 53
- 239000012263 liquid product Substances 0.000 claims abstract description 50
- 238000002360 preparation method Methods 0.000 claims abstract description 38
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 125000002091 cationic group Chemical group 0.000 claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 claims abstract description 25
- 239000007788 liquid Substances 0.000 claims abstract description 22
- 238000005352 clarification Methods 0.000 claims abstract description 21
- 210000004027 cell Anatomy 0.000 claims description 96
- 230000009467 reduction Effects 0.000 claims description 31
- 235000013601 eggs Nutrition 0.000 claims description 26
- 230000002779 inactivation Effects 0.000 claims description 25
- 238000005199 ultracentrifugation Methods 0.000 claims description 25
- 238000005119 centrifugation Methods 0.000 claims description 21
- 239000002245 particle Substances 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 238000004587 chromatography analysis Methods 0.000 claims description 18
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 17
- 241000712461 unidentified influenza virus Species 0.000 claims description 15
- 239000012530 fluid Substances 0.000 claims description 12
- 238000001042 affinity chromatography Methods 0.000 claims description 11
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 11
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 10
- 244000309457 enveloped RNA virus Species 0.000 claims description 10
- -1 quaternary ammonium cations Chemical class 0.000 claims description 10
- 238000011210 chromatographic step Methods 0.000 claims description 9
- 108010067390 Viral Proteins Proteins 0.000 claims description 8
- 238000004255 ion exchange chromatography Methods 0.000 claims description 8
- 230000003381 solubilizing effect Effects 0.000 claims description 8
- 101710163270 Nuclease Proteins 0.000 claims description 7
- 241000450599 DNA viruses Species 0.000 claims description 6
- 108010052285 Membrane Proteins Proteins 0.000 claims description 5
- 102000018697 Membrane Proteins Human genes 0.000 claims description 5
- 238000011118 depth filtration Methods 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 230000001902 propagating effect Effects 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 208000037262 Hepatitis delta Diseases 0.000 claims description 4
- 241000724709 Hepatitis delta virus Species 0.000 claims description 4
- 210000004102 animal cell Anatomy 0.000 claims description 4
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 4
- 241000711573 Coronaviridae Species 0.000 claims description 3
- 241000711950 Filoviridae Species 0.000 claims description 3
- 241000710831 Flavivirus Species 0.000 claims description 3
- 241000287828 Gallus gallus Species 0.000 claims description 3
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 claims description 3
- 241000713112 Orthobunyavirus Species 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 238000004062 sedimentation Methods 0.000 claims description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 241000712891 Arenavirus Species 0.000 claims description 2
- 208000037797 influenza A Diseases 0.000 claims description 2
- 208000037798 influenza B Diseases 0.000 claims description 2
- 208000037799 influenza C Diseases 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 10
- 238000000926 separation method Methods 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 65
- 101710154606 Hemagglutinin Proteins 0.000 description 61
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 61
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 61
- 101710176177 Protein A56 Proteins 0.000 description 61
- 239000000185 hemagglutinin Substances 0.000 description 61
- 229920001429 chelating resin Polymers 0.000 description 33
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 31
- 230000007928 solubilization Effects 0.000 description 26
- 238000005063 solubilization Methods 0.000 description 26
- 102000005348 Neuraminidase Human genes 0.000 description 24
- 108010006232 Neuraminidase Proteins 0.000 description 24
- 239000012535 impurity Substances 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 17
- 229920000053 polysorbate 80 Polymers 0.000 description 17
- 239000000872 buffer Substances 0.000 description 12
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 11
- 230000000644 propagated effect Effects 0.000 description 11
- 238000000108 ultra-filtration Methods 0.000 description 10
- 230000007423 decrease Effects 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 229960000380 propiolactone Drugs 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 229920000136 polysorbate Polymers 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 230000000415 inactivating effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229940124873 Influenza virus vaccine Drugs 0.000 description 4
- 108010058846 Ovalbumin Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000011026 diafiltration Methods 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000001932 seasonal effect Effects 0.000 description 4
- 229940031626 subunit vaccine Drugs 0.000 description 4
- 229960004854 viral vaccine Drugs 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101710085938 Matrix protein Proteins 0.000 description 3
- 101710127721 Membrane protein Proteins 0.000 description 3
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 108010065667 Viral Matrix Proteins Proteins 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229960003971 influenza vaccine Drugs 0.000 description 3
- 238000004460 liquid liquid chromatography Methods 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 229920000151 polyglycol Polymers 0.000 description 3
- 239000010695 polyglycol Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 description 2
- SHRYOWAOIIMOSO-UHFFFAOYSA-N 2-(octadecylamino)acetic acid Chemical compound CCCCCCCCCCCCCCCCCCNCC(O)=O SHRYOWAOIIMOSO-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 2
- HXYCHJFUBNTKQR-RNFRBKRXSA-N (2R,3R)-heptane-1,2,3-triol Chemical compound CCCC[C@@H](O)[C@H](O)CO HXYCHJFUBNTKQR-RNFRBKRXSA-N 0.000 description 1
- SIDULKZCBGMXJL-UHFFFAOYSA-N 1-dimethylphosphoryldodecane Chemical compound CCCCCCCCCCCCP(C)(C)=O SIDULKZCBGMXJL-UHFFFAOYSA-N 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 241000713297 Influenza C virus Species 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 229910001423 beryllium ion Inorganic materials 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- OXJUJQDEISSCTB-UHFFFAOYSA-N but-3-en-2-imine Chemical compound CC(=N)C=C OXJUJQDEISSCTB-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- WOQQAWHSKSSAGF-WXFJLFHKSA-N decyl beta-D-maltopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 WOQQAWHSKSSAGF-WXFJLFHKSA-N 0.000 description 1
- GSVLCKASFMVUSW-UHFFFAOYSA-N decyl(dimethyl)phosphine oxide Chemical compound CCCCCCCCCCP(C)(C)=O GSVLCKASFMVUSW-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- UMWKZHPREXJQGR-UHFFFAOYSA-N n-methyl-n-(2,3,4,5,6-pentahydroxyhexyl)decanamide Chemical compound CCCCCCCCCC(=O)N(C)CC(O)C(O)C(O)C(O)CO UMWKZHPREXJQGR-UHFFFAOYSA-N 0.000 description 1
- GCRLIVCNZWDCDE-SJXGUFTOSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]nonanamide Chemical compound CCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO GCRLIVCNZWDCDE-SJXGUFTOSA-N 0.000 description 1
- SBWGZAXBCCNRTM-CTHBEMJXSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]octanamide Chemical compound CCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SBWGZAXBCCNRTM-CTHBEMJXSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161509630P | 2011-07-20 | 2011-07-20 | |
| US61/509,630 | 2011-07-20 | ||
| EP11174660.8 | 2011-07-20 | ||
| EP11174660 | 2011-07-20 | ||
| PCT/EP2012/063045 WO2013010797A1 (en) | 2011-07-20 | 2012-07-04 | Process for producing viral antigen and vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014101484A RU2014101484A (ru) | 2015-07-27 |
| RU2565827C2 true RU2565827C2 (ru) | 2015-10-20 |
Family
ID=45094875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014101484/10A RU2565827C2 (ru) | 2011-07-20 | 2012-07-04 | Способ получения вирусного антигена и вакцин |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2734619B1 (enExample) |
| JP (1) | JP6275641B2 (enExample) |
| KR (2) | KR20140038530A (enExample) |
| CN (1) | CN103827296B (enExample) |
| AU (1) | AU2012286098C1 (enExample) |
| BR (1) | BR112014001049A2 (enExample) |
| CA (1) | CA2841604C (enExample) |
| ES (1) | ES2653197T3 (enExample) |
| MX (1) | MX2014000753A (enExample) |
| RU (1) | RU2565827C2 (enExample) |
| TW (1) | TW201311896A (enExample) |
| WO (1) | WO2013010797A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2807176C2 (ru) * | 2018-11-15 | 2023-11-10 | БАЙЕР ХелсКер ЛЛСи | Способы инактивации вируса для непрерывного получения антител |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109568573A (zh) * | 2014-12-12 | 2019-04-05 | 普莱柯生物工程股份有限公司 | 疫苗组合物及其制备方法和应用 |
| SG11202004725PA (en) | 2017-12-19 | 2020-07-29 | CSL Behring Lengnau AG | Protein purification and virus inactivation with alkyl glycosides |
| JP7360594B2 (ja) * | 2017-12-28 | 2023-10-13 | 共立製薬株式会社 | ワクチン製剤、並びに魚類のイリドウイルス感染症予防方法 |
| US11696948B2 (en) | 2018-06-12 | 2023-07-11 | Kbio Holdings Limited | Vaccines formed by virus and antigen conjugation |
| US11529413B2 (en) | 2018-06-12 | 2022-12-20 | Kbio Holdings Limited | Virus and antigen purification and conjugation |
| KR102714626B1 (ko) | 2018-06-12 | 2024-10-08 | 케이바이오 홀딩스 리미티드 | 바이러스 및 항원 정제 및 접합 |
| US11690907B2 (en) | 2018-06-12 | 2023-07-04 | Kbio Holdings Limited | Vaccines formed by virus and antigen conjugation |
| JP2021528999A (ja) * | 2018-07-04 | 2021-10-28 | プロバイオジェン アーゲー | エンベロープウイルスの精製方法 |
| JP7518825B2 (ja) | 2018-11-15 | 2024-07-18 | バイエル・ヘルスケア・エルエルシー | 抗体の連続的製造のためのウイルス不活化方法 |
| RU2710239C1 (ru) * | 2019-06-14 | 2019-12-25 | Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства | Способ получения антигена или антигенов для производства противогриппозной вакцины и вакцина на его основе |
| EP4054630A2 (en) * | 2019-11-07 | 2022-09-14 | Seqirus UK Limited | Compositions and methods for producing a viral vaccine with reduced particle size |
| KR102546626B1 (ko) * | 2020-04-29 | 2023-06-21 | 에스케이바이오사이언스(주) | 인플루엔자 바이러스 항원 정제 조건 신속 확인 시험 |
| EP4144753A4 (en) * | 2020-04-29 | 2024-12-25 | SK Bioscience Co., Ltd. | Influenza virus production method using disposable culture process system, and test for quickly checking conditions for influenza virus antigen purification |
| CN112309502B (zh) * | 2020-10-14 | 2024-09-20 | 深圳市新合生物医疗科技有限公司 | 一种计算肿瘤新抗原负荷的方法及系统 |
| JP2023141423A (ja) * | 2022-03-24 | 2023-10-05 | 国立大学法人 東京大学 | ウイルスの精製方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987002250A1 (en) * | 1984-11-01 | 1987-04-23 | Bror Morein | A process for preparing immunogenic complex |
| RU2283139C1 (ru) * | 2005-03-21 | 2006-09-10 | Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации | Способ получения антигенов для вакцины против вирусов гриппа |
| EP1982727A1 (en) * | 2007-04-17 | 2008-10-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for purification of viral proteins |
| WO2009115917A2 (en) * | 2008-03-18 | 2009-09-24 | Novartis Ag | Improvements in preparation of influenza virus vaccine antigens |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4140762A (en) * | 1974-01-14 | 1979-02-20 | Sandoz Ltd. | Influenza sub-unit vaccine |
| US4240762A (en) * | 1979-03-12 | 1980-12-23 | Johnston Pump Company | Seal-aligning rigid coupling assembly |
| EP1597400B8 (en) * | 2003-02-25 | 2013-10-09 | MedImmune, LLC | Methods of producing influenza vaccine compositions |
| WO2009029695A1 (en) * | 2007-08-28 | 2009-03-05 | Baxter International Inc. | Method for producing viral vaccines |
| AU2009296628B2 (en) * | 2008-09-24 | 2015-01-15 | Medimmune, Llc | Methods for purification of viruses |
| US8202726B2 (en) * | 2008-09-24 | 2012-06-19 | Medimmune, Llc | Methods for cultivating cells, propagating and purifying viruses |
| GB0918830D0 (en) * | 2009-10-27 | 2009-12-09 | Glaxosmithkline Biolog Niederl | Process |
-
2012
- 2012-07-04 RU RU2014101484/10A patent/RU2565827C2/ru not_active IP Right Cessation
- 2012-07-04 KR KR1020147001348A patent/KR20140038530A/ko not_active Ceased
- 2012-07-04 ES ES12734892.8T patent/ES2653197T3/es active Active
- 2012-07-04 MX MX2014000753A patent/MX2014000753A/es not_active Application Discontinuation
- 2012-07-04 JP JP2014520591A patent/JP6275641B2/ja not_active Expired - Fee Related
- 2012-07-04 BR BR112014001049A patent/BR112014001049A2/pt not_active IP Right Cessation
- 2012-07-04 WO PCT/EP2012/063045 patent/WO2013010797A1/en not_active Ceased
- 2012-07-04 CA CA2841604A patent/CA2841604C/en not_active Expired - Fee Related
- 2012-07-04 EP EP12734892.8A patent/EP2734619B1/en active Active
- 2012-07-04 AU AU2012286098A patent/AU2012286098C1/en not_active Ceased
- 2012-07-04 CN CN201280035724.9A patent/CN103827296B/zh not_active Expired - Fee Related
- 2012-07-04 KR KR1020167020663A patent/KR20160096215A/ko not_active Withdrawn
- 2012-07-19 TW TW101126141A patent/TW201311896A/zh unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987002250A1 (en) * | 1984-11-01 | 1987-04-23 | Bror Morein | A process for preparing immunogenic complex |
| RU2283139C1 (ru) * | 2005-03-21 | 2006-09-10 | Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации | Способ получения антигенов для вакцины против вирусов гриппа |
| EP1982727A1 (en) * | 2007-04-17 | 2008-10-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for purification of viral proteins |
| WO2009115917A2 (en) * | 2008-03-18 | 2009-09-24 | Novartis Ag | Improvements in preparation of influenza virus vaccine antigens |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2807176C2 (ru) * | 2018-11-15 | 2023-11-10 | БАЙЕР ХелсКер ЛЛСи | Способы инактивации вируса для непрерывного получения антител |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012286098C1 (en) | 2016-09-15 |
| RU2014101484A (ru) | 2015-07-27 |
| EP2734619A1 (en) | 2014-05-28 |
| BR112014001049A2 (pt) | 2017-02-21 |
| KR20160096215A (ko) | 2016-08-12 |
| KR20140038530A (ko) | 2014-03-28 |
| CA2841604A1 (en) | 2013-01-24 |
| EP2734619B1 (en) | 2017-09-06 |
| CN103827296B (zh) | 2016-11-16 |
| TW201311896A (zh) | 2013-03-16 |
| AU2012286098A1 (en) | 2014-01-23 |
| JP2014524747A (ja) | 2014-09-25 |
| WO2013010797A1 (en) | 2013-01-24 |
| MX2014000753A (es) | 2014-05-07 |
| CA2841604C (en) | 2020-01-21 |
| JP6275641B2 (ja) | 2018-02-07 |
| CN103827296A (zh) | 2014-05-28 |
| ES2653197T3 (es) | 2018-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2565827C2 (ru) | Способ получения вирусного антигена и вакцин | |
| AU2012286098B2 (en) | Process for producing viral antigen and vaccines | |
| US10329536B2 (en) | Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an MDCK cell suspension culture | |
| JP5264843B2 (ja) | 細胞培養におけるインフルエンザウイルスの複製の方法、および本方法によって入手可能なインフルエンザウイルス | |
| KR19980081114A (ko) | 인플루엔자 백신 | |
| NZ532203A (en) | Cell culture system in which cell growth and virus multiplication occur concurrently | |
| EP3068791A1 (en) | Removal of residual cell culture impurities | |
| JP6851827B2 (ja) | 細胞培養中でのウイルスの大規模製造 | |
| EP3234113B1 (en) | A method for a large scale virus purification | |
| US20110293660A1 (en) | Novel method | |
| KR101581228B1 (ko) | 바이러스의 증식을 위한 ２-단계 온도 프로파일 | |
| HK1194763A (en) | Process for producing viral antigen and vaccines | |
| US20230220356A1 (en) | Compositions and methods for producing a viral vaccine with reduced particle size |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20170705 |